Stocktoria
Equillium, Inc. EQ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-10-12
Equillium, Inc. statistics & valuation
Market cap$192.8M
P / B6.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -20.1% | -40.2% | -393.9% | — |
| Net margin | — | -19.6% | -37.0% | -396.1% | — |
| FCF margin | — | -46.5% | -60.5% | -57.2% | — |
| Return on assets | -70.2% | -31.5% | -26.4% | -79.6% | -45.7% |
| Return on equity | -78.3% | -42.3% | -59.1% | -195.4% | -58.7% |
| Debt / equity | — | — | — | 0.28× | 0.15× |
| Current ratio | 10.58 | 3.93 | 1.79 | 2.40 | 9.35 |
| Revenue growth | — | 13.9% | 129.0% | — | — |
Source: SEC EDGAR filings · CIK 0001746466 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.